Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?
Hepatology
.
2018 Mar;67(3):826-828.
doi: 10.1002/hep.29617.
Epub 2018 Jan 30.
Authors
Shuichi Aoki
1
,
Mark Cobbold
2
,
Andrew X Zhu
2
,
Dan G Duda
1
Affiliations
1
Edwin L. Steele Laboratories, Department of Radiation Oncology.
2
Department of Medicine, Massachusetts General Hospital Harvard Medical School, Boston, MA.
PMID:
29077214
PMCID:
PMC5826834
DOI:
10.1002/hep.29617
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Carcinoma, Hepatocellular*
Drug Delivery Systems
Humans
Liver Neoplasms
Nanomedicine*
Grants and funding
P01 CA080124/CA/NCI NIH HHS/United States
R41 CA213678/CA/NCI NIH HHS/United States